TNFRSF17 Expression serves as an inclusion eligibility criterion in 9 clinical trials, of which 8 are open and 1 is closed. Of the trials that contain TNFRSF17 Expression as an inclusion criterion, 2 are early phase 1 (2 open), 6 are phase 1 (5 open), and 1 is phase 1/phase 2 (1 open).
Trials with TNFRSF17 Expression in the inclusion eligibility criteria most commonly target multiple myeloma and B-cell neoplasm .
Idecabtagene vicleucel, cyclophosphamide, fludarabine, gc012f, and autologous anti-bcma-car-expressing cd4+/cd8+ t-lymphocytes fcarh143 are the most frequent therapies in trials with TNFRSF17 Expression as an inclusion criteria .
Significance of TNFRSF17 Expression in Diseases
Multiple Myeloma +
TNFRSF17 Expression is an inclusion criterion in 8 clinical trials for multiple myeloma, of which 7 are open and 1 is closed. Of the trials that contain TNFRSF17 Expression and multiple myeloma as inclusion criteria, 2 are early phase 1 (2 open) and 6 are phase 1 (5 open) .
B-Cell Neoplasm +
TNFRSF17 Expression is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF17 Expression and B-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.